Theratechnologies initiated with a Buy at JonesTrading

JonesTrading analyst Justin Walsh initiated coverage of Theratechnologies with a Buy rating and $6 price target. Theratechnologies is a commercial-stage biopharmaceutical company headquartered in Montreal with two approved and marketed drugs in its North America-focused HIV franchise, Walsh tells investors in a research note. The analyst expects growth in the HIV-franchise to support the company’s "increasingly important oncology pipeline." He thinks investors underappreciate the potential of Theratechnologies’ earlier stage development efforts.